Day: February 17, 2026

Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy

BRISBANE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform...

Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases

In two non-GLP studies, CUE-401 was well tolerated with no adverse events observed Proof-of-concept studies reinforce promising preclinical profile and...

Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on...

error: Content is protected !!